

NXY-059 for the Treatment of Acute Ischemic Stroke

New England Journal of Medicine

357, 562-571

DOI: [10.1056/nejmoa070240](https://doi.org/10.1056/nejmoa070240)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute Ischemic Stroke. , 0, , 242-256.		0
2	NXY-059 for the Treatment of Stroke. New England Journal of Medicine, 2007, 357, 2198-2199.	13.9	5
3	Neuroprotection in Cerebral Infarction: The Opportunity of New Studies. Cerebrovascular Diseases, 2007, 24, 153-156.	0.8	28
4	Response to Letter by Fisher et al. Stroke, 2007, 38, .	1.0	1
5	Acute Ischemic Stroke. New England Journal of Medicine, 2007, 357, 572-579.	13.9	313
6	Female gonadal hormones, migraine, and spreading depression. Annals of Neurology, 2007, 62, 678-679.	2.8	0
7	Neuroprotection in the SAINTâ€”II aftermath. Annals of Neurology, 2007, 62, 677-678.	2.8	7
9	Poxvirus-derived cytokine response modifier A (CrmA) does not protect against focal cerebral ischemia in mice. Brain Research, 2007, 1185, 293-300.	1.1	4
10	Stroke pathophysiology: management challenges and new treatment advances. Journal of Physiology and Biochemistry, 2007, 63, 261-277.	1.3	12
13	Intravenous rt-PA versus endovascular therapy for acute ischemic stroke. Current Atherosclerosis Reports, 2008, 10, 332-338.	2.0	6
14	Aortic occlusion for cerebral ischemia: From theory to practice. Current Cardiology Reports, 2008, 10, 31-36.	1.3	46
15	Neuroprotection in cerebral ischemia: Emphasis on the SAINT trial. Current Cardiology Reports, 2008, 10, 37-42.	1.3	25
16	Treatment of childhood arterial ischemic stroke. Annals of Neurology, 2008, 63, 679-696.	2.8	56
17	Antioxidative and thrombolytic TMP nitron for treatment of ischemic stroke. Bioorganic and Medicinal Chemistry, 2008, 16, 8868-8874.	1.4	67
18	Laser Therapy in Acute Stroke Treatment. International Journal of Stroke, 2008, 3, 88-91.	2.9	12
19	Permanent Middle Cerebral Artery Occlusion in Sheep: A Novel Large Animal Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1951-1964.	2.4	88
20	Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. British Journal of Pharmacology, 2008, 153, S44-54.	2.7	90
21	The use of the Chandler loop to examine the interaction potential of NXYâ€”059 on the thrombolytic properties of rtPA on human thrombi <i>in vitro</i>. British Journal of Pharmacology, 2008, 153, 124-131.	2.7	23

#	ARTICLE	IF	CITATIONS
22	Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. <i>British Journal of Pharmacology</i> , 2008, 153, S325-38.	2.7	147
23	Experimental models, neurovascular mechanisms and translational issues in stroke research. <i>British Journal of Pharmacology</i> , 2008, 153, S396-405.	2.7	97
24	Clinical pharmacological issues in the development of acute stroke therapies. <i>British Journal of Pharmacology</i> , 2008, 153, S112-9.	2.7	32
25	A new penumbra: transitioning from injury into repair after stroke. <i>Nature Medicine</i> , 2008, 14, 497-500.	15.2	536
26	The adult human brain in preclinical drug development. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 659-666.	21.5	108
27	Nitrones as therapeutics. <i>Free Radical Biology and Medicine</i> , 2008, 45, 1361-1374.	1.3	188
28	Stroke: encouragement and disappointment in clinical trials. <i>Lancet Neurology</i> , The, 2008, 7, 5-7.	4.9	8
29	Neuroprotectants in stroke therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 887-900.	0.9	21
30	Management of Acute Ischemic Stroke. <i>Neurologic Clinics</i> , 2008, 26, 345-371.	0.8	10
31	Neuroprotection for ischemic stroke: Past, present and future. <i>Neuropharmacology</i> , 2008, 55, 363-389.	2.0	672
32	Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. <i>Progress in Neurobiology</i> , 2008, 85, 273-296.	2.8	80
33	Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors. <i>Postgraduate Medical Journal</i> , 2008, 84, 361-367.	0.9	45
34	The Nitrone Free Radical Scavenger NXY-059 Is Neuroprotective when Administered after Traumatic Brain Injury in the Rat. <i>Journal of Neurotrauma</i> , 2008, 25, 1449-1457.	1.7	31
35	Pharmacokinetics of 8-hour intravenous infusion of NXY-059: A phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. <i>Clinical Therapeutics</i> , 2008, 30, 2342-2353.	1.1	7
36	Drugs acting on SUR1 to treat CNS ischemia and trauma. <i>Current Opinion in Pharmacology</i> , 2008, 8, 42-49.	1.7	52
37	Carbamylated erythropoietin to treat neuronal injury: new development strategies. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1175-1186.	1.9	33
38	Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. <i>Cerebrovascular Diseases</i> , 2008, 25, 457-507.	0.8	2,222
39	Recommendations and treatment strategies for the management of acute ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1071-1085.	0.9	44

#	ARTICLE	IF	CITATIONS
40	The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator. <i>Cerebrovascular Diseases</i> , 2008, 26, 360-366.	0.8	48
41	Chapter 59 Approaches to neuroprotective and reperfusion injury therapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 94, 1205-1223.	1.0	4
42	Chapter 6 Reperfusion injury after stroke: neurovascular proteases and the blood-brain barrier. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 92, 117-136.	1.0	10
43	Targeting Extracellular Matrix Proteolysis for Hemorrhagic Complications of tPA Stroke Therapy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2008, 7, 235-242.	0.8	39
44	Comments Regarding the Recent OAST Article. <i>Stroke</i> , 2008, 39, e14; author reply e15.	1.0	2
45	A Critique of SAINT II. <i>Stroke</i> , 2008, 39, 1389-1391.	1.0	32
46	Is It Time to Definitely Abandon Neuroprotection in Acute Ischemic Stroke?. <i>Stroke</i> , 2008, 39, 1659-1660.	1.0	29
47	Advances in Emerging Therapies 2007. <i>Stroke</i> , 2008, 39, 255-257.	1.0	6
48	Recurrent Events in Transient Ischemic Attack and Minor Stroke. <i>Stroke</i> , 2008, 39, 2461-2466.	1.0	77
49	Does Hemispheric Lateralization Influence Functional and Cardiovascular Outcomes After Stroke?. <i>Stroke</i> , 2008, 39, 3335-3340.	1.0	68
50	Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood-brain barrier. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 167-179.	1.5	4
52	Efficacité de la coccinelle <i>Stethorus punctillum</i> (Weise) comme prédateur de l'acarien <i>Oligonychus afrasiaticus</i> (McGregor) dans les palmeraies de la région d'Ouargla en Algérie. <i>Fruits</i> , 2008, 63, 85-92.	0.3	9
53	Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 259-270.	1.4	59
55	NXY-059 for the Treatment of Acute Stroke. <i>Stroke</i> , 2008, 39, 1751-1758.	1.0	222
56	DP-b99, a Membrane-Activated Metal Ion Chelator, as Neuroprotective Therapy in Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1774-1778.	1.0	61
57	Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality. <i>Stroke</i> , 2008, 39, 2824-2829.	1.0	279
58	Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 473-493.	1.2	210
59	The hard way to acute stroke treatment. <i>Journal of Hypertension</i> , 2008, 26, 2274-2275.	0.3	0

#	ARTICLE	IF	CITATIONS
60	Neuroprotection by angiotensin receptor blockers?. Journal of Hypertension, 2008, 26, 853.	0.3	1
61	Development and efficacy of NXY-059 for the treatment of acute ischemic stroke. Future Neurology, 2008, 3, 229-240.	0.9	10
62	Neuropathology and pathophysiology of stroke. , 0, , 1-27.		4
63	Multimodal MRI for Ischemic Stroke: From Acute Therapy to Preventive Strategies. Journal of Clinical		

#	ARTICLE	IF	CITATIONS
79	Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke. <i>Stroke</i> , 2009, 40, 3067-3072.	1.0	95
80	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009, 11, 860-885.	0.7	104
81	Neuroinflammation and Neuroprotective Strategies in Acute Ischaemic Stroke - from bench to bedside. <i>Current Molecular Medicine</i> , 2009, 9, 336-354.	0.6	49
82	Emerging drugs for acute ischemic stroke. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 33-42.	1.0	5
83	Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 2009, 40, e647-56.	1.0	509
85	Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke. <i>Current Medicinal Chemistry</i> , 2009, 16, 4593-4600.	1.2	136
86	Stroke Outcome in Clinical Trial Patients Deriving From Different Countries. <i>Stroke</i> , 2009, 40, 35-40.	1.0	37
87	The Free Radical Scavenger Edaravone Rescues Rats from Cerebral Infarction by Attenuating the Release of High-Mobility Group Box-1 in Neuronal Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 865-874.	1.3	57
88	Mechanisms and targets for angiogenic therapy after stroke. <i>Cell Adhesion and Migration</i> , 2009, 3, 216-223.	1.1	99
89	Pyruvate protects against experimental stroke via an anti-inflammatory mechanism. <i>Neurobiology of Disease</i> , 2009, 36, 223-231.	2.1	73
90	The effect of tempol on endothelium-dependent vasodilatation and blood pressure. , 2009, 122, 109-124.		68
91	Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke. <i>BMC Neuroscience</i> , 2009, 10, 82.	0.8	6
92	Early Renal Ischemia-Reperfusion Injury in Humans Is Dominated by IL-6 Release from the Allograft. <i>American Journal of Transplantation</i> , 2009, 9, 1574-1584.	2.6	58
93	S-Allyl L-cysteine diminishes cerebral ischemia-induced mitochondrial dysfunctions in hippocampus. <i>Brain Research</i> , 2009, 1265, 128-137.	1.1	49
94	Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: A systematic review. <i>Brain Research Reviews</i> , 2009, 62, 71-82.	9.1	62
95	Therapeutic Strategy for Ischemic Stroke. <i>Neurochemical Research</i> , 2009, 34, 707-710.	1.6	12
96	Dantrolene: Mechanisms of Neuroprotection and Possible Clinical Applications in the Neurointensive Care Unit. <i>Neurocritical Care</i> , 2009, 10, 103-115.	1.2	68
97	Dissociation and Protection of the Neurovascular Unit after Thrombolysis and Reperfusion in Ischemic Rat Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 715-725.	2.4	166

#	ARTICLE	IF	CITATIONS
98	Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. <i>FEBS Journal</i> , 2009, 276, 2-12.	2.2	45
99	Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. <i>British Journal of Pharmacology</i> , 2009, 157, 1157-1171.	2.7	111
100	Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice. <i>British Journal of Pharmacology</i> , 2009, 157, 1154-1156.	2.7	71
101	Current Status of Neuroprotection for Cerebral Ischemia. <i>Stroke</i> , 2009, 40, S111-4.	1.0	251
102	Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 323-331.	0.9	43
104	Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 1121-1125.	1.0	59
105	Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. <i>Neuroscience</i> , 2009, 160, 755-766.	1.1	26
106	Delayed Detection of Atrial Fibrillation after Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 453-457.	0.7	45
107	Inflammatory mechanisms in ischemic stroke: therapeutic approaches. <i>Journal of Translational Medicine</i> , 2009, 7, 97.	1.8	888
108	Catalytic Antioxidants and Neurodegeneration. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 555-569.	2.5	53
109	The role of neurotrophic factors in the pathology and treatment of multiple sclerosis. <i>Immunopharmacology and Immunotoxicology</i> , 2009, 31, 32-38.	1.1	18
110	Neuronal functionality assessed by magnetoencephalography is related to oxidative stress system in acute ischemic stroke. <i>NeuroImage</i> , 2009, 44, 1267-1273.	2.1	39
111	The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: A combination therapy study with tissue plasminogen activator. <i>Experimental Neurology</i> , 2009, 215, 95-100.	2.0	40
114	Reactive Oxygen Species in Diabetes-induced Vascular Damage, Stroke, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 775-785.	1.2	41
116	Gene and Stem Cell Therapy in Ischemic Stroke. <i>Cell Transplantation</i> , 2009, 18, 999-1002.	1.2	32
117	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference – research perspectives in AF™. <i>European Heart Journal</i> , 2009, 30, 2969-2980.	1.0	173
118	To Phase 3 or Not to Phase 3?. <i>Stroke</i> , 2009, 40, 1553-1554.	1.0	2
120	Alcohol Consumption and Functional Outcome After Stroke in Men. <i>Stroke</i> , 2010, 41, 141-146.	1.0	27

#	ARTICLE	IF	CITATIONS
122	Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Archiv European Journal of Physiology, 2010, 460, 525-542.	1.3	936
123	Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development. Translational Stroke Research, 2010, 1, 96-107.	2.3	69
124	Free radical scavengers and spin traps – therapeutic implications for ischemic stroke. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2010, 24, 511-520.	1.7	18
125	Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Research, 2010, 1307, 22-27.	1.1	69
126	Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2010, 31, 796-806.	1.9	34
127	Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. Journal of Neurochemistry, 2010, 113, 303-312.	2.1	39
128	The Virtual International Stroke Trials Archive (VISTA): Results and Impact on Future Stroke Trials and Management of Stroke Patients. International Journal of Stroke, 2010, 5, 103-109.	2.9	13
129	VISTA-Rehab: A Resource for Stroke Rehabilitation Trials. International Journal of Stroke, 2010, 5, 447-452.	2.9	8
130	The neurovascular unit in the setting of stroke. Journal of Internal Medicine, 2010, 267, 156-171.	2.7	238
131	Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. Okayama Igakkai Zasshi, 2010, 122, 195-197.	0.0	6
132	Cerebrolysin for acute ischaemic stroke. International Journal of Risk and Safety in Medicine, 2010, 22, 179-193.	0.3	6
133	Migraine and Functional Outcome From Ischemic Cerebral Events in Women. Circulation, 2010, 122, 2551-2557.	1.6	48
134	Is There a Future for Neuroprotective Agents in Cardiac Surgery?. Seminars in Cardiothoracic and Vascular Anesthesia, 2010, 14, 123-135.	0.4	3
135	The Biochemical Basis of Hydroxymethylglutaryl-CoA Reductase Inhibitors as Neuroprotective Agents in Aneurysmal Subarachnoid Hemorrhage. Pharmaceuticals, 2010, 3, 3186-3199.	1.7	6
136	Can Animal Models of Disease Reliably Inform Human Studies?. PLoS Medicine, 2010, 7, e1000245.	3.9	1,026
137	Can Molecular and Cellular Neuroprotection Be Translated Into Therapies for Patients?. Stroke, 2010, 41, S87-90.	1.0	45
138	Neuroprotection by S-PBN in hyperglycemic ischemic brain injury in rats. Upsala Journal of Medical Sciences, 2010, 115, 163-168.	0.4	5
139	Gestione dell'infarto cerebrale acuto. EMC - Neurologia, 2010, 10, 1-13.	0.0	0

#	ARTICLE	IF	CITATIONS
141	Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!. Expert Opinion on Investigational Drugs, 2010, 19, 1179-1186.	1.9	15
142	Edaravone: A new therapeutic approach for the treatment of acute stroke. Medical Hypotheses, 2010, 75, 583-585.	0.8	21
143	The Science of Stroke: Mechanisms in Search of Treatments. Neuron, 2010, 67, 181-198.	3.8	1,628
144	Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends in Pharmacological Sciences, 2010, 31, 596-604.	4.0	485
145	Cerebrolysin for acute ischaemic stroke. , 2010, , CD007026.		13
146	Excitotoxicity*. , 2010, , 515-535.		2
147	Molecular Imaging for Integrated Medical Therapy and Drug Development. , 2010, , .		6
148	Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke. Clinics in Geriatric Medicine, 2010, 26, 125-147.	1.0	38
149	Taking a light approach to treating acute ischemic stroke patients: Transcranial near-infrared laser therapy translational science. Annals of Medicine, 2010, 42, 576-586.	1.5	88
150	Effects of Edaravone on Muscle Atrophy and Locomotor Function in Patients with Ischemic Stroke. Drugs in R and D, 2010, 10, 155-163.	1.1	30
151	A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?. Expert Opinion on Pharmacotherapy, 2010, 11, 1753-1763.	0.9	179
153	Beyond neurological disease: New targets for edaravone (Review). International Journal of Molecular Medicine, 2011, 28, 899-906.	1.8	32
154	The Ischemic Penumbra: Correlates in Imaging and Implications for Treatment of Ischemic Stroke. Cerebrovascular Diseases, 2011, 32, 307-320.	0.8	137
156	Neuronal Calcium Homeostasis and Dysregulation. Antioxidants and Redox Signaling, 2011, 14, 1261-1273.	2.5	259
157	Antioxidant Therapy: Current Status and Future Prospects. Current Medicinal Chemistry, 2011, 18, 3871-3888.	1.2	365
158	The Handbook of Neuroprotection. , 2011, , .		29
159	New era for drug discovery and development in renal disease. Nature Reviews Nephrology, 2011, 7, 469-477.	4.1	17
160	Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies. , 2011, , 1-24.		4

#	ARTICLE	IF	CITATIONS
161	Oxidative Stress in Ischemic Brain Damage: Mechanisms of Cell Death and Potential Molecular Targets for Neuroprotection. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 1505-1517.	2.5	644
162	II. Cerebral Infarction/Transient Ischemic Attack (TIA). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2011, 20, S31-S73.	0.7	56
163	Cytoprotective protein C pathways and implications for stroke and neurological disorders. <i>Trends in Neurosciences</i> , 2011, 34, 198-209.	4.2	129
164	A α and A β but not C-fibres are involved in stroke related pain and allodynia: an experimental study in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 452-456.	1.2	28
165	Translating promising preclinical neuroprotective therapies to human stroke trials. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 433-449.	0.6	46
166	TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. <i>Experimental Neurology</i> , 2011, 227, 224-231.	2.0	68
167	Clinical Scales to Assess Patients with Stroke. , 2011, , 307-333.		0
168	Pharmacologic Modification of Acute Cerebral Ischemia. , 2011, , 1049-1083.		1
169	The Potential of Tetrandrine as a Protective Agent for Ischemic Stroke. <i>Molecules</i> , 2011, 16, 8020-8032.	1.7	35
170	Vascular Protection and Restorative Therapy in Ischemic Stroke. <i>Cell Transplantation</i> , 2011, 20, 95-97.	1.2	32
171	Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 771-775.	0.8	28
172	Novel Situations of Endothelial Injury in Stroke – Mechanisms of Stroke and Strategy of Drug Development: Intracranial Bleeding Associated With the Treatment of Ischemic Stroke: Thrombolytic Treatment of Ischemia-Affected Endothelial Cells With Tissue-Type Plasminogen Activator. <i>Journal of Pharmacological Sciences</i> , 2011, 116, 25-29.	1.1	24
174	Bridging the translation gap – new hopes, new challenges. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 163-171.	1.0	16
175	Identification of oxidized serum albumin in the cerebrospinal fluid of ischaemic stroke patients. <i>European Journal of Neurology</i> , 2011, 18, 1151-1158.	1.7	22
176	Validation Assessment of Risk Scores to Predict Postthrombolysis Intracerebral Haemorrhage. <i>International Journal of Stroke</i> , 2011, 6, 109-111.	2.9	17
177	Calculation of Numbers-Needed-To-Treat in Parallel Group Trials Assessing Ordinal Outcomes: Case Examples from Acute Stroke and Stroke Prevention. <i>International Journal of Stroke</i> , 2011, 6, 472-479.	2.9	21
178	The Future of Basic Science Research and Stroke: Hubris and Translational Stroke Research. <i>International Journal of Stroke</i> , 2011, 6, 412-413.	2.9	2
179	Nanotubes reduce stroke damage. <i>Nature Nanotechnology</i> , 2011, 6, 83-84.	15.6	20

#	ARTICLE	IF	CITATIONS
180	Taking a closer look at conductivity. <i>Nature Nanotechnology</i> , 2011, 6, 84-85.	15.6	4
181	Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke. <i>Brain Research</i> , 2011, 1410, 120-121.	1.1	11
182	Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. <i>ACS Symposium Series</i> , 2011, , 255-288.	0.5	19
183	CeeToxâ„¢ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut. <i>Translational Stroke Research</i> , 2011, 2, 51-59.	2.3	27
184	Resolving the Negative Data Publication Dilemma in Translational Stroke Research. <i>Translational Stroke Research</i> , 2011, 2, 1-6.	2.3	18
185	Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles?. <i>Translational Stroke Research</i> , 2011, 2, 138-143.	2.3	41
186	De-Risking of Stilbazulenyl Nitron (STAZN), a Lipophilic Nitron to Treat Stroke Using a Unique Panel of In Vitro Assays. <i>Translational Stroke Research</i> , 2011, 2, 209-217.	2.3	16
187	Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. <i>Translational Stroke Research</i> , 2011, 2, 129-135.	2.3	32
188	Post-stroke infection: A systematic review and meta-analysis. <i>BMC Neurology</i> , 2011, 11, 110.	0.8	555
189	Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. <i>BMC Neurology</i> , 2011, 11, 39.	0.8	56
190	Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. <i>Molecular Neurodegeneration</i> , 2011, 6, 11.	4.4	431
191	Neurological and pathological improvements of cerebral infarction in mice with platinum nanoparticles. <i>Journal of Neuroscience Research</i> , 2011, 89, 1125-1133.	1.3	49
192	Sulfonylurea Use Before Stroke Does Not Influence Outcome. <i>Stroke</i> , 2011, 42, 710-715.	1.0	30
193	Frequent Early Cardiac Complications Contribute to Worse Stroke Outcome in Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2011, 32, 454-460.	0.8	34
194	Trafermin for stroke recovery: is it time for another randomized clinical trial?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1533-1541.	1.4	19
195	Neuroprotection by local intra-arterial infusion of erythropoietin after focal cerebral ischemia in rats. <i>Neurological Research</i> , 2011, 33, 520-528.	0.6	29
196	IV thrombolysis and statins. <i>Neurology</i> , 2011, 77, 888-895.	1.5	65
197	Neuroprotective Efficacy from a Lipophilic Redox-Modulating Mn(III) <i>N</i> -Hexylpyridylporphyrin, MnTnHex-2-PyP: Rodent Models of Ischemic Stroke and Subarachnoid Hemorrhage. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 906-916.	1.3	60

#	ARTICLE	IF	CITATIONS
198	Neuroinflammation and Cerebrovascular Disease in Old Age: A Translational Medicine Perspective. <i>Journal of Aging Research</i> , 2011, 2011, 1-18.	0.4	35
199	Efficacy and safety of thrombolysis in patients aged 80 years or above with major acute ischemic stroke. <i>Neurology India</i> , 2012, 60, 373.	0.2	2
200	Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 14470-14491.	1.8	6
201	Neuroprotection for Stroke: Current Status and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2012, 13, 11753-11772.	1.8	169
202	Sisyphus and Translational Stroke Research. <i>Science Translational Medicine</i> , 2012, 4, 156ps20.	5.8	7
203	Two Centuries of Neurology and Psychiatry in the <i>Journal</i>. <i>New England Journal of Medicine</i> , 2012, 367, 58-65.	13.9	5
204	Granulocyte-Colony Stimulating Factor for Mobilizing Bone Marrow Stem Cells in Subacute Stroke. <i>Stroke</i> , 2012, 43, 405-411.	1.0	99
205	Spinal cord injury clinical trials translational process, review of past and proposed acute trials with reference to recommended trial guidelines. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 109, 386-397.	1.0	6
206	New Vessels after Stroke: Postischemic Neovascularization and Regeneration. <i>Cerebrovascular Diseases</i> , 2012, 33, 492-499.	0.8	82
207	Determining the Feasibility of Ambulance-Based Randomised Controlled Trials in Patients with Ultra-Acute Stroke: Study Protocol for the 'Rapid Intervention with GTN in Hypertensive Stroke Trial' (RIGHT, ISRCTN66434824). <i>Stroke Research and Treatment</i> , 2012, 2012, 1-10.	0.5	12
208	Statistical Analysis of the Primary Outcome in Acute Stroke Trials. <i>Stroke</i> , 2012, 43, 1171-1178.	1.0	216
209	Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges. <i>Current Immunology Reviews</i> , 2012, 8, 39-49.	1.2	0
210	Animal Models in Neurology: Drawbacks and Opportunities. <i>Current Pharmaceutical Design</i> , 2012, 18, 4443-4452.	0.9	3
211	Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke. <i>Current Pharmaceutical Design</i> , 2012, 18, 3677-3684.	0.9	20
212	Ischemic Stroke and Glucose Intolerance: a Review of the Evidence and Exploration of Novel Therapeutic Targets. <i>Journal of Pharmacological Sciences</i> , 2012, 118, 1-13.	1.1	40
213	Impact of Disability Status on Ischemic Stroke Costs in Canada in the First Year. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 793-800.	0.3	96
214	Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review). <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 3-8.	0.8	64
215	The Two Pathophysiologies of Focal Brain Ischemia: Implications for Translational Stroke Research. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1310-1316.	2.4	180

#	ARTICLE	IF	CITATIONS
216	Neuroprotection in Stroke. , 2012, , 79-97.		0
217	Neuroanesthesia: from bench to bed. Journal of Anesthesia, 2012, 26, 585-588.	0.7	5
218	Cyclin-Dependent Kinase Inhibition With Roscovitine: Neuroprotection in Acute Ischemic Stroke. Clinical Pharmacology and Therapeutics, 2012, 91, 327-332.	2.3	12
219	The importance of early brain injury after subarachnoid hemorrhage. Progress in Neurobiology, 2012, 97, 14-37.	2.8	475
220	Discharge Destination as a Surrogate for Modified Rankin Scale Defined Outcomes at 3- and 12-Months Poststroke Among Stroke Survivors. Archives of Physical Medicine and Rehabilitation, 2012, 93, 1408-1413.e1.	0.5	134
221	The 1027th target candidate in stroke: Will NADPH oxidase hold up?. Experimental & Translational Stroke Medicine, 2012, 4, 11.	3.2	37
222	Suppression of the inflammatory response by diphenyleioidonium after transient focal cerebral ischemia. Journal of Neurochemistry, 2012, 123, 98-107.	2.1	17
223	Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Research, 2012, 1489, 113-120.	1.1	40
224	Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy, 2012, 8, 77-87.	4.3	290
225	Transgenic Overexpression of Peroxiredoxin-2 Attenuates Ischemic Neuronal Injury <i>Via</i> Suppression of a Redox-Sensitive Pro-Death Signaling Pathway. Antioxidants and Redox Signaling, 2012, 17, 719-732.	2.5	72
226	Xenon Neuroprotection in Experimental Stroke. Anesthesiology, 2012, 117, 1262-1275.	1.3	60
227	Brain Protection Therapy in Acute Cerebral Infarction. Journal of Nippon Medical School, 2012, 79, 104-110.	0.3	11
229	To serve and neuroprotect. Nature Medicine, 2012, 18, 1003-1006.	15.2	10
230	GM1485, a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke. Journal of Neuroscience Research, 2012, 90, 1413-1423.	1.3	2
231	A Clinically Relevant Rabbit Embolic Stroke Model for Acute Ischemic Stroke Therapy Development: Mechanisms and Targets. , 2012, , 541-584.		6
232	Cerebrolysin in Patients With Acute Ischemic Stroke in Asia. Stroke, 2012, 43, 630-636.	1.0	115
233	Nonhuman Primate Models of Stroke for Translational Neuroprotection Research. Neurotherapeutics, 2012, 9, 371-379.	2.1	117
234	Coffee Component 3-Caffeoylquinic Acid Increases Antioxidant Capacity but not Polyphenol Content in Experimental Cerebral Infarction. Neurochemical Research, 2012, 37, 1085-1090.	1.6	6

#	ARTICLE	IF	CITATIONS
235	Cynandione A mitigates ischemic injuries in rats with cerebral ischemia. <i>Journal of Neurochemistry</i> , 2012, 121, 451-464.	2.1	20
236	Using human pluripotent stem cells to study post-transcriptional mechanisms of neurodegenerative diseases. <i>Brain Research</i> , 2012, 1462, 129-138.	1.1	4
237	Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside. <i>International Journal of Stroke</i> , 2012, 7, 407-418.	2.9	224
238	An agenda for UK clinical pharmacology: From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 959-967.	1.1	6
239	Is there a future for neuroprotective agents in acute ischaemic stroke?. <i>European Journal of Neurology</i> , 2012, 19, 797-798.	1.7	5
240	Ginsenosideâ€Rd improves outcome of acute ischaemic stroke â€“ a randomized, doubleâ€blind, placeboâ€controlled, multicenter trial. <i>European Journal of Neurology</i> , 2012, 19, 855-863.	1.7	66
241	Antioxidant Strategies in Neurocritical Care. <i>Neurotherapeutics</i> , 2012, 9, 44-55.	2.1	23
242	RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research. <i>Translational Stroke Research</i> , 2013, 4, 279-285.	2.3	240
243	Drug-Like Property Profiling of Novel Neuroprotective Compounds to Treat Acute Ischemic Stroke: Guidelines to Develop Pleiotropic Molecules. <i>Translational Stroke Research</i> , 2013, 4, 328-342.	2.3	17
244	Experimental Models of Vascular Occlusions for Evaluation of Thrombectomy Devices. <i>Cardiovascular Engineering and Technology</i> , 2013, 4, 309-322.	0.7	3
245	Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke. <i>Systematic Reviews</i> , 2013, 2, 33.	2.5	43
246	Design of Poly(ethylene Glycol)-Functionalized Hydrophilic Carbon Clusters for Targeted Therapy of Cerebrovascular Dysfunction in Mild Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2013, 30, 789-796.	1.7	37
247	Albumin for hyperacute stroke: another failed neuroprotectant. <i>Lancet Neurology</i> , The, 2013, 12, 1036-1037.	4.9	3
248	Guidelines for the Early Management of Patients With Acute Ischemic Stroke. <i>Stroke</i> , 2013, 44, 870-947.	1.0	5,246
249	High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 1049-1058.	4.9	152
250	Neuroprotective effect through the cerebral sodiumâ€glucose transporter on the development of ischemic damage in global ischemia. <i>Brain Research</i> , 2013, 1541, 61-68.	1.1	27
251	Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: the Time for Treatment Is Now. <i>Translational Stroke Research</i> , 2013, 4, 704-709.	2.3	16
252	Evidence and Rational Based Research on Chinese Drugs. , 2013, , .		19

#	ARTICLE	IF	CITATIONS
253	Which NADPH Oxidase Isoform Is Relevant for Ischemic Stroke? The Case for Nox 2. Antioxidants and Redox Signaling, 2013, 18, 1400-1417.	2.5	110
254	Neuroprotection After Stroke by Targeting NOX4 As a Source of Oxidative Stress. Antioxidants and Redox Signaling, 2013, 18, 1418-1427.	2.5	126
255	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs. Journal of Alzheimer's Disease, 2013, 34, 1-114.	1.2	23
256	The human sulfatase 2 inhibitor 2,4-disulfonylphenylacetate butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGF β 1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes and Cancer, 2013, 52, 225-236.	1.5	50
257	Involvement of LPA1 receptor signaling in cerebral ischemia-induced neuropathic pain. Neuroscience, 2013, 235, 10-15.	1.1	33
258	Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia. Neuropharmacology, 2013, 67, 403-411.	2.0	25
259	Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?. Kidney International, 2013, 84, 693-702.	2.6	60
260	Infarctus cérébraux sus-tentoriels graves : prise en charge en réanimation. , 2013, , 57-81.		0
261	Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers. Journal of Medicinal Chemistry, 2013, 56, 3121-3147.	2.9	121
262	Enhanced Neuroprotective Effects of Resveratrol Delivered by Nanoparticles on Hydrogen Peroxide-Induced Oxidative Stress in Rat Cortical Cell Culture. Molecular Pharmaceutics, 2013, 10, 2045-2053.	2.3	50
263	PP2A Ligand ITH12246 Protects against Memory Impairment and Focal Cerebral Ischemia in Mice. ACS Chemical Neuroscience, 2013, 4, 1267-1277.	1.7	20
264	Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions. Future Medicinal Chemistry, 2013, 5, 465-478.	1.1	11
265	The effect of the ALAnerv nutritional supplement on some oxidative stress markers in postacute stroke patients undergoing rehabilitation. Applied Physiology, Nutrition and Metabolism, 2013, 38, 613-620.	0.9	5
266	The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. Journal of Neurosurgery, 2013, 118, 1072-1085.	0.9	75
267	Intracerebral Hemorrhage. Neurosurgery Clinics of North America, 2013, 24, 349-359.	0.8	29
269	Molecular Mechanisms of Ischemia-Reperfusion Injury in Brain: Pivotal Role of the Mitochondrial Membrane Potential in Reactive Oxygen Species Generation. Molecular Neurobiology, 2013, 47, 9-23.	1.9	511
270	Chinese Medicine Neuroaid Efficacy on Stroke Recovery. Stroke, 2013, 44, 2093-2100.	1.0	80
271	Evidence-based Translational Medicine. Stroke, 2013, 44, 1466-1471.	1.0	22

#	ARTICLE	IF	CITATIONS
272	Results of Membrane-activated Chelator Stroke Intervention Randomized Trial of DP-b99 in Acute Ischemic Stroke. <i>Stroke</i> , 2013, 44, 580-584.	1.0	32
273	Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013, 34, 96-103.	1.0	72
274	Melatonin-Based Therapeutics for Neuroprotection in Stroke. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8924-8947.	1.8	32
275	Drug Therapy in Stroke: From Preclinical to Clinical Studies. <i>Pharmacology</i> , 2013, 92, 324-334.	0.9	68
276	Progesterone Treatment for Experimental Stroke: An Individual Animal Meta-Analysis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1362-1372.	2.4	47
277	Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. <i>Stroke</i> , 2013, 44, 3529-3536.	1.0	56
278	M9, A Novel Region of Amino-terminus of Nogo-66, Attenuates Cerebral Ischemic Injury by Inhibiting NADPH Oxidase-Derived Superoxide Production in Mice. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 319-328.	1.9	11
279	Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke. <i>Frontiers in Neurology</i> , 2013, 4, 32.	1.1	292
280	NADPH Oxidase as a Therapeutic Target for Neuroprotection against Ischaemic Stroke: Future Perspectives. <i>Brain Sciences</i> , 2013, 3, 561-598.	1.1	39
281	Drugs from Natural Substances: Why Study Them in Cerebral Infarction. <i>Cerebrovascular Diseases</i> , 2013, 35, IV-VI.	0.8	1
282	Failures, Mistakes and Shortcomings of My Stroke Trials. <i>Cerebrovascular Diseases</i> , 2013, 36, 250-256.	0.8	0
283	Biochemical Basis and Therapeutic Implications of Angiogenesis. , 2013, , .		5
284	Prevention of Post-Stroke Disuse Muscle Atrophy with a Free Radical Scavenger. <i>Frontiers of Neurology and Neuroscience</i> , 2013, 32, 139-147.	3.0	10
285	Nonconvulsive seizures after subarachnoid hemorrhage: Multimodal detection and outcomes. <i>Annals of Neurology</i> , 2013, 74, 53-64.	2.8	162
286	Stroke: Pathophysiology and Therapy. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2013, 5, 1-91.	0.3	0
287	Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 603-613.	1.4	31
288	Neuroprotective agents in ischemic stroke: past failures and future opportunities. <i>Clinical Investigation</i> , 2013, 3, 1167-1177.	0.0	10
289	Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke. <i>Biomedical Reports</i> , 2013, 1, 7-12.	0.9	38

#	ARTICLE	IF	CITATIONS
290	Recommendations and Practices to Optimize Stroke Therapy. <i>Stroke</i> , 2013, 44, 841-843.	1.0	39
292	Lipoxygenase: An Emerging Target for Stroke Therapy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 191-199.	0.8	39
293	Clinical translational failure in neuroprotective agents: the steps from animal experiments to clinical trials. <i>Medical Science Monitor Basic Research</i> , 2013, 19, 37-45.	2.6	86
294	Quantification of Errors in Ordinal Outcome Scales Using Shannon Entropy: Effect on Sample Size Calculations. <i>PLoS ONE</i> , 2013, 8, e67754.	1.1	18
295	The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13909-13930.	1.8	87
296	Biomarkers for Stroke. <i>Journal of Stroke</i> , 2013, 15, 27.	1.4	58
297	The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke. <i>Recent Patents on CNS Drug Discovery</i> , 2013, 8, 2-12.	0.9	29
298	Oxidative Stress and the Use of Antioxidants in Stroke. <i>Antioxidants</i> , 2014, 3, 472-501.	2.2	209
300	EVIDENCE BASE OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE USE IN PATIENTS WITH STROKE AND ITS CONSEQUENCES. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 448-456.	0.3	3
301	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. <i>Disease-Modifying Drugs. Update 2014. Journal of Alzheimer's Disease</i> , 2014, 42, 1079-1149.	1.2	5
302	Optimising outcome assessment to improve quality and efficiency of stroke trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 101-111.	0.7	8
303	Antioxidants: The new frontier for translational research in cerebroprotection. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2014, 30, 160.	0.2	25
304	The Yin and Yang of Innate Immunity in Stroke. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	31
305	Attenuation of urokinase activity during experimental ischaemia protects the cerebral barrier from damage through regulation of matrix metalloproteinase-2 and NAD(P)H oxidase. <i>European Journal of Neuroscience</i> , 2014, 39, 2119-2128.	1.2	14
306	Of mice and men: modelling post-stroke depression experimentally. <i>British Journal of Pharmacology</i> , 2014, 171, 4673-4689.	2.7	59
307	Progesterone for Traumatic Brain Injury – Resisting the Sirens' Song. <i>New England Journal of Medicine</i> , 2014, 371, 2522-2523.	13.9	40
308	Current state of the opportunities for derivation of germ-like cells from pluripotent stem cells: are you a man, or a mouse?. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 184-191.	0.5	5
309	Rodent models of ischemic stroke lack translational relevance are baboon models the answer?. <i>Neurological Research</i> , 2014, 36, 417-422.	0.6	17

#	ARTICLE	IF	CITATIONS
310	Importance of Preclinical Research in the Development of Neuroprotective Strategies for Ischemic Stroke. <i>JAMA Neurology</i> , 2014, 71, 634.	4.5	52
311	Glutamate as a Neurotoxin. , 2014, , 365-397.		2
312	Characteristic Adverse Events and Their Incidence Among Patients Participating in Acute Ischemic Stroke Trials. <i>Stroke</i> , 2014, 45, 2677-2682.	1.0	14
313	Translational Research in Acute Central Nervous System Injury. <i>JAMA Neurology</i> , 2014, 71, 1311.	4.5	30
314	Characterization of a New Model of Thromboembolic Stroke in C57 black/6J mice. <i>Translational Stroke Research</i> , 2014, 5, 526-533.	2.3	22
315	Small molecule inhibitors in the treatment of cerebral ischemia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 659-680.	0.9	3
316	Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 453-460.	4.9	218
317	Guidelines for the treatment of acute ischaemic stroke. <i>NeurologÃa (English Edition)</i> , 2014, 29, 102-122.	0.2	37
318	Pre-treatment with the synthetic antioxidant Tâ€butyl bisphenol protects cerebral tissues from experimental ischemia reperfusion injury. <i>Journal of Neurochemistry</i> , 2014, 130, 733-747.	2.1	15
319	GuÃa para el tratamiento del infarto cerebral agudo. <i>NeurologÃa</i> , 2014, 29, 102-122.	0.3	109
320	Translational paradigms in pharmacology and drug discovery. <i>Biochemical Pharmacology</i> , 2014, 87, 189-210.	2.0	31
321	Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 185-199.	2.4	423
322	Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. <i>Brain Research</i> , 2014, 1588, 159-167.	1.1	16
323	Biotherapies in stroke. <i>Revue Neurologique</i> , 2014, 170, 779-798.	0.6	40
324	A novel tetramethylpyrazine bis-nitrone (TN-2) protects against 6-hydroxyldopamine-induced neurotoxicity via modulation of the NF- κ B and the PKC β /PI3-K/Akt pathways. <i>Neurochemistry International</i> , 2014, 78, 76-85.	1.9	25
325	Neurogenesis and Inflammation after Ischemic Stroke: What is Known and Where We Go from Here. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1573-1584.	2.4	299
326	Simple Biological Systems for Assessing the Activity of Superoxide Dismutase Mimics. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2416-2436.	2.5	48
327	Clinical Trials in Acute Ischemic Stroke. <i>CNS Drugs</i> , 2014, 28, 929-938.	2.7	62

#	ARTICLE	IF	CITATIONS
328	Found in Translation. Stroke, 2014, 45, 1510-1518.	1.0	132
329	Small synthetic hyaluronan disaccharides afford neuroprotection in brain ischemia-related models. Neuroscience, 2014, 265, 313-322.	1.1	3
330	Acute therapies for stroke. , 0, , 294-310.		0
331	Therapeutic Effects of Multifunctional Tetramethylpyrazine Nitron on Models of Parkinson's Disease <i>in Vitro</i> and <i>in Vivo</i>. Biological and Pharmaceutical Bulletin, 2014, 37, 274-285.	0.6	36
334	Two decades testing interventions in transgenic mouse models of Alzheimer's disease: designing and interpreting studies for clinical trial success. Clinical Investigation, 2014, 4, 693-704.	0.0	5
335	Combination of early and delayed ischemic postconditioning enhances brain-derived neurotrophic factor production by upregulating the ERK-CREB pathway in rats with focal ischemia. Molecular Medicine Reports, 2015, 12, 6427-6434.	1.1	21
336	The role of microglia and myeloid immune cells in acute cerebral ischemia. Frontiers in Cellular Neuroscience, 2014, 8, 461.	1.8	203
337	A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Scientific Reports, 2015, 5, 13428.	1.6	30
338	Ameliorative effects of Gualou Guizhi decoction on inflammation in focal cerebral ischemic-reperfusion injury. Molecular Medicine Reports, 2015, 12, 988-994.	1.1	14
339	Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials, 2015, 16, 561.	0.7	17
340	Cerebrolysin for acute ischaemic stroke. , 2015, , CD007026.		13
341	Targeting to acute cerebral ischemic stroke and new pathology based on materials' translocation between bloodstream and organs/tissues. Drug Delivery System, 2015, 30, 317-326.	0.0	0
342	Clinical neurorestorative progress in stroke. Journal of Neurorestoratology, 0, , 63.	1.1	9
343	Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease. International Journal of Molecular Sciences, 2015, 16, 18185-18223.	1.8	58
344	Analysis of Cynandione's Anti-Ischemic Stroke Effects from Pathways and Protein-Protein Interactome. PLoS ONE, 2015, 10, e0124632.	1.1	4
345	Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Translational Stroke Research, 2015, 6, 264-275.	2.3	84
346	Neurointervention and Neuroprotection in Stroke. , 2015, , 331-341.		0
347	Mitochondrial Reactive Oxygen Species at the Heart of the Matter. Circulation Research, 2015, 116, 1783-1799.	2.0	159

#	ARTICLE	IF	CITATIONS
348	An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke. <i>Translational Stroke Research</i> , 2015, 6, 451-457.	2.3	12
349	Treatment of acute cerebral ischemia using animal models: a meta-analysis. <i>Translational Neuroscience</i> , 2015, 6, 47-58.	0.7	6
350	Neuroprotective effects of pretreatment with macrolide antibiotics on cerebral ischemia reperfusion injury. <i>Neurological Research</i> , 2015, 37, 514-524.	0.6	11
351	Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. <i>Experimental Neurology</i> , 2015, 265, 142-151.	2.0	47
352	Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 8-24.	5.7	162
353	Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 623-643.	1.9	33
354	Design of acute neuroprotection studies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 128, 761-778.	1.0	16
355	Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 2033-2040.	1.7	58
356	Antioxidants in Translational Medicine. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 1130-1143.	2.5	201
357	Improving early clinical trial phase identification of promising therapeutics. <i>Neurology</i> , 2015, 85, 274-283.	1.5	10
358	Prehospital stroke care: telemedicine, thrombolysis and neuroprotection. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 753-761.	1.4	6
359	The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. <i>Thrombosis Research</i> , 2015, 135, 1209-1213.	0.8	17
360	Large Animal Models of Ischemic Cardiomyopathy: Are They Enough to Bridge the Translational Gap?. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 666-672.	1.4	5
361	The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals. <i>European Journal of Pharmacology</i> , 2015, 759, 3-13.	1.7	41
362	Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis. <i>JAMA Neurology</i> , 2015, 72, 423.	4.5	97
363	Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 888-901.	2.4	405
364	Neuroprotection in ischemic stroke: what does the future hold?. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 227-229.	1.4	14
365	Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study. <i>BMC Neurology</i> , 2015, 15, 120.	0.8	26

#	ARTICLE	IF	CITATIONS
366	Neuroprotection and Neurorepair. , 2015, , 625-637.		0
367	Neurointervention in the Medical Specialties. , 2015, , .		2
368	Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview. Clinical Neurology and Neurosurgery, 2015, 129, 1-9.	0.6	86
369	Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature. International Journal of Neuroscience, 2015, 125, 555-565.	0.8	38
370	Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxidants and Redox Signaling, 2015, 23, 460-489.	2.5	56
371	Apigenin-7-O-β-D-(6''-p-coumaroyl)-Glucopyranoside Treatment Elicits Neuroprotective Effect against Experimental Ischemic Stroke. International Journal of Biological Sciences, 2016, 12, 42-52.	2.6	31
372	Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1010-1013.	0.8	0
373	Mitochondrion-Permeable Antioxidants to Treat ROS-Burst-Mediated Acute Diseases. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	56
374	Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. ELife, 2016, 5, .	2.8	73
376	Targeting oxidative stress for the treatment of ischemic stroke: Upstream and downstream therapeutic strategies. Brain Circulation, 2016, 2, 153.	0.7	99
377	Statins in prevention and treatment of ischemic stroke. Human Physiology, 2016, 42, 858-864.	0.1	0
378	Biochemistry of Nitric Oxide and Peroxynitrite: Sources, Targets and Biological Implications. , 2016, , 49-77.		5
379	Cerebrolysin for acute ischaemic stroke. , 2016, 12, CD007026.		36
380	Neuroprotective effects of erythromycin on ischemic injury following permanent focal cerebral ischemia in rats. Neurological Research, 2016, 38, 275-284.	0.6	10
381	Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1984-1996.	0.7	59
382	In vivo whole brain, cellular and molecular imaging in nonhuman primate models of neuropathology. Neuroscience and Biobehavioral Reviews, 2016, 66, 104-118.	2.9	15
383	Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurology, The, 2016, 15, 869-881.	4.9	842
384	A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model. Neuroscience Letters, 2016, 633, 7-13.	1.0	46

#	ARTICLE	IF	CITATIONS
385	The Primary Outcome Is Positive â€” Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016, 375, 971-979.	13.9	112
386	Is the Oxidative Stress Really a Disease?. <i>Acta Marisiensis - Seria Medica</i> , 2016, 62, 112-120.	0.3	7
387	Intracellular disulfide reduction by phosphine-borane complexes: Mechanism of action for neuroprotection. <i>Neurochemistry International</i> , 2016, 99, 24-32.	1.9	12
388	Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. <i>Annals of Neurology</i> , 2016, 79, 560-568.	2.8	35
389	Non-Neuronal Mechanisms of Brain Damage and Repair After Stroke. <i>Springer Series in Translational Stroke Research</i> , 2016, , .	0.1	1
390	Expanding the concept of neuroprotection for acute ischemic stroke: The pivotal roles of reperfusion and the collateral circulation. <i>Progress in Neurobiology</i> , 2016, 145-146, 46-77.	2.8	69
391	Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke. <i>Journal of Neuroinflammation</i> , 2016, 13, 119.	3.1	74
392	Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice. <i>Translational Stroke Research</i> , 2016, 7, 535-547.	2.3	88
393	Gestione dellâ€™infarto cerebrale acuto. <i>EMC - Neurologia</i> , 2016, 16, 1-22.	0.0	0
394	Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy. <i>Scientific Reports</i> , 2016, 6, 37148.	1.6	27
395	Pro-oxidant Nrf2 inducers: Promiscuity and protection. <i>Vascular Pharmacology</i> , 2016, 87, 26-29.	1.0	0
396	Nitrones as Potent Anticancer Therapeutics. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 245-264.	0.4	2
398	Ethical considerations and challenges in first-in-human research. <i>Translational Research</i> , 2016, 177, 6-18.	2.2	5
399	Embracing Biological and Methodological Variance in a New Approach to Pre-Clinical Stroke Testing. <i>Translational Stroke Research</i> , 2016, 7, 274-283.	2.3	14
400	Clinical Scales to Assess Patients with Stroke. , 2016, , 308-325.e6.		2
401	Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics. <i>Stroke</i> , 2016, 47, 1278-1285.	1.0	16
402	Pharmacokinetics of 21 active components in focal cerebral ischemic rats after oral administration of the active fraction of Xiao-Xu-Ming decoction. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 122, 110-117.	1.4	16
403	Intravenous Thrombolysis. , 2016, , 826-848.		1

#	ARTICLE	IF	CITATIONS
404	Pharmacologic Modification of Acute Cerebral Ischemia. , 2016, , 916-936.e5.		0
405	Cofilin as a Promising Therapeutic Target for Ischemic and Hemorrhagic Stroke. Translational Stroke Research, 2016, 7, 33-41.	2.3	48
406	Regulatory aspects of small molecule drugs for heart regeneration. Advanced Drug Delivery Reviews, 2016, 96, 245-252.	6.6	7
407	Leukemia Inhibitory Factor Protects Neurons from Ischemic Damage via Upregulation of Superoxide Dismutase 3. Molecular Neurobiology, 2017, 54, 608-622.	1.9	32
408	Systematic Review and Meta-analysis: Important Tools in Understanding Drug Development for Stroke. Springer Series in Translational Stroke Research, 2017, , 73-93.	0.1	0
409	Targeting PSD-95 as a Novel Approach in the Treatment of Stroke. Springer Series in Translational Stroke Research, 2017, , 157-184.	0.1	1
410	Ischemic stroke: experimental models and reality. Acta Neuropathologica, 2017, 133, 245-261.	3.9	425
411	Therapeutic Strategies Harnessing Oxidative Stress to Treat Stroke. Oxidative Stress in Applied Basic Research and Clinical Practice, 2017, , 113-133.	0.4	0
412	Targeting Oxidative Stress in Stroke. Springer Series in Translational Stroke Research, 2017, , 203-250.	0.1	8
413	YAMATO Study (Tissue-Type Plasminogen Activator and Edoxaban Combination Therapy). Stroke, 2017, 48, 712-719.	1.0	34
414	Cerebrolysin for acute ischaemic stroke. The Cochrane Library, 2017, 4, CD007026.	1.5	22
415	Self-contained, low-cost Body-on-a-Chip systems for drug development. Experimental Biology and Medicine, 2017, 242, 1701-1713.	1.1	50
416	Combining Neuroprotection With Endovascular Treatment of Acute Stroke. Stroke, 2017, 48, 1700-1705.	1.0	44
417	Neuroprotection in the Treatment of Acute Ischemic Stroke. Progress in Cardiovascular Diseases, 2017, 59, 542-548.	1.6	126
418	Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection. Pharmaceutical Research, 2017, 34, 378-393.	1.7	18
419	Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke, 2017, 48, 2007-2012.	1.0	421
420	Mechanisms of Acupuncture Therapy for Cerebral Ischemia: an Evidence-Based Review of Clinical and Animal Studies on Cerebral Ischemia. Journal of NeuroImmune Pharmacology, 2017, 12, 575-592.	2.1	41
421	Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain, 2017, 140, 2079-2092.	3.7	153

#	ARTICLE	IF	CITATIONS
422	Erythropoietin: Endogenous Protection of Ischemic Brain. <i>Vitamins and Hormones</i> , 2017, 105, 197-232.	0.7	19
423	Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. <i>Neurosurgical Focus</i> , 2017, 42, E3.	1.0	60
425	Stroke outcomes are worse with larger leukoaraiosis volumes. <i>Brain</i> , 2017, 140, 158-170.	3.7	96
426	Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke. <i>Neurochemistry International</i> , 2017, 107, 23-32.	1.9	81
428	Brain Angiogenesis After Stroke. , 2017, , 473-494.		3
429	Discrepancy and Pitfalls of Clinical Practice Guideline. , 2017, , 371-379.		0
430	Effects of standard ethanolic extract from <i>Erythrina velutina</i> in acute cerebral ischemia in mice. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1230-1239.	2.5	27
431	Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. <i>Life Sciences</i> , 2017, 168, 7-15.	2.0	15
432	Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine Derivatives as Potential Neuroprotective Agents. <i>Chemical and Pharmaceutical Bulletin</i> , 2017, 65, 56-65.	0.6	16
433	Geometries of vasculature bifurcation can affect the level of trophic damage during formation of a brain ischemic lesion. <i>Biochemical Society Transactions</i> , 2017, 45, 1097-1103.	1.6	8
434	Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 240-253.	0.9	75
435	A Review of Neuroinflammatory Mechanisms in Ischemic Stroke: Background and Therapeutic Approaches. , 2017, , .		1
436	PHARMACOLOGICAL TREATMENT OF ACUTE ISCHEMIC STROKE: A REVIEW. <i>International Research Journal of Pharmacy</i> , 2017, 8, 23-29.	0.0	0
437	Improving Cerebral Blood Flow after Arterial Recanalization: A Novel Therapeutic Strategy in Stroke. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2669.	1.8	65
438	Blood Pressure and Penumbra Sustainance in Stroke from Large Vessel Occlusion. <i>Frontiers in Neurology</i> , 2017, 8, 317.	1.1	83
439	Rethinking Neuroprotection in Severe Traumatic Brain Injury: Toward Bedside Neuroprotection. <i>Frontiers in Neurology</i> , 2017, 8, 354.	1.1	31
440	Constitutive Expression of Adiponectin in Endothelial Progenitor Cells Protects a Rat Model of Cerebral Ischemia. <i>Neural Plasticity</i> , 2017, 2017, 1-8.	1.0	9
442	Neuroprotective Effect and Mechanism of Action of Tetramethylpyrazine Nitron for Ischemic Stroke Therapy. <i>NeuroMolecular Medicine</i> , 2018, 20, 97-111.	1.8	28

#	ARTICLE	IF	CITATIONS
443	Improving Microcirculatory Reperfusion Reduces Parenchymal Oxygen Radical Formation and Provides Neuroprotection. <i>Stroke</i> , 2018, 49, 1267-1275.	1.0	30
444	NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2158-2165.	0.7	20
445	Deletion of NADPH oxidase 4 reduces severity of traumatic brain injury. <i>Free Radical Biology and Medicine</i> , 2018, 117, 66-75.	1.3	32
446	Experimental models of focal and multifocal cerebral ischemia: a review. <i>Reviews in the Neurosciences</i> , 2018, 29, 661-674.	1.4	7
447	Development of a reactive oxygen species-sensitive nitric oxide synthase inhibitor for the treatment of ischemic stroke. <i>Free Radical Biology and Medicine</i> , 2018, 115, 395-404.	1.3	31
448	Propagation of free-radical reactions in concentrated protein solutions. <i>Free Radical Research</i> , 2018, 52, 159-170.	1.5	13
449	NADPH oxidases in traumatic brain injury – Promising therapeutic targets?. <i>Redox Biology</i> , 2018, 16, 285-293.	3.9	84
450	Enhancing Scientific Foundations to Ensure Reproducibility. <i>American Journal of Pathology</i> , 2018, 188, 6-10.	1.9	16
451	Mitochondrial targeting as a novel therapy for stroke. <i>Brain Circulation</i> , 2018, 4, 84.	0.7	50
452	Molecular Basis of Resilience. , 2018, , .		1
454	Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 132.	1.8	173
455	Treatment duration affects cytoprotective efficacy of positive allosteric modulation of $\alpha 7$ nAChRs after focal ischemia in rats. <i>Pharmacological Research</i> , 2018, 136, 121-132.	3.1	9
456	A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2073-2091.	2.4	124
457	Ultrasound-Enhanced Protective Effect of Tetramethylpyrazine via the ROS/HIF-1A Signaling Pathway in an in Vitro Cerebral Ischemia/Reperfusion Injury Model. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1786-1798.	0.7	13
458	Cerebral Ischemic Reperfusion Injuries (CIRI). <i>Springer Series in Translational Stroke Research</i> , 2018, , .	0.1	0
459	Oxidative Stress and Nitric Oxide in Cerebral Ischemic Reperfusion Injury. <i>Springer Series in Translational Stroke Research</i> , 2018, , 101-119.	0.1	1
460	Understanding the Role of Dysfunctional and Healthy Mitochondria in Stroke Pathology and Its Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2127.	1.8	18
461	Efficacy of Novel Carbon Nanoparticle Antioxidant Therapy in a Severe Model of Reversible Middle Cerebral Artery Stroke in Acutely Hyperglycemic Rats. <i>Frontiers in Neurology</i> , 2018, 9, 199.	1.1	37

#	ARTICLE	IF	CITATIONS
462	Refocusing Neuroprotection in Cerebral Reperfusion Era: New Challenges and Strategies. <i>Frontiers in Neurology</i> , 2018, 9, 249.	1.1	69
463	Targeting NMDA receptors in stroke: new hope in neuroprotection. <i>Molecular Brain</i> , 2018, 11, 15.	1.3	217
464	Contribution of Zinc-Dependent Delayed Calcium Influx via TRPC5 in Oxidative Neuronal Death and its Prevention by Novel TRPC Antagonist. <i>Molecular Neurobiology</i> , 2019, 56, 2822-2835.	1.9	20
465	Physiologic Implications of Reactive Oxygen Species Production by Mitochondrial Complex I Reverse Electron Transport. <i>Antioxidants</i> , 2019, 8, 285.	2.2	57
466	Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-26.	1.9	388
467	The complexities of behavioural assessment in neurodegenerative disorders: A focus on Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 147, 104363.	3.1	9
468	Central Nervous System Drug Delivery After Ischemic or Hemorrhagic Stroke. , 2019, , 473-500.		2
469	Acute Therapies for Stroke. , 2019, , 315-332.		0
470	Oxidative stress-responsive apoptosis inducing protein (ORAIP) plays a critical role in cerebral ischemia/reperfusion injury. <i>Scientific Reports</i> , 2019, 9, 13512.	1.6	42
471	Reactivities of MeO-substituted PBN-type nitrones. <i>New Journal of Chemistry</i> , 2019, 43, 15754-15762.	1.4	6
472	Pharmacodynamic Effect of Ellagic Acid on Ameliorating Cerebral Ischemia/Reperfusion Injury. <i>Pharmacology</i> , 2019, 104, 320-331.	0.9	13
474	Key Role of Cytochrome C for Apoptosis Detection Using Raman Microimaging in an Animal Model of Brain Ischemia with Insulin Treatment. <i>Applied Spectroscopy</i> , 2019, 73, 1208-1217.	1.2	15
475	Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats. <i>Journal of Molecular Neuroscience</i> , 2019, 68, 590-602.	1.1	6
476	Intravenous Magnesium Sulfate in Acute Stroke. <i>Stroke</i> , 2019, 50, 931-938.	1.0	17
477	The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest. <i>Free Radical Biology and Medicine</i> , 2019, 136, 87-95.	1.3	31
478	Design of Meta-Analysis Studies. <i>Handbook of Experimental Pharmacology</i> , 2019, 257, 299-317.	0.9	4
479	Reproducibility and Rigor in Animal-Based Research. <i>ILAR Journal</i> , 2019, 60, 17-23.	1.8	66
480	Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate. <i>Free Radical Biology and Medicine</i> , 2019, 134, 9-22.	1.3	44

#	ARTICLE	IF	CITATIONS
481	The role of reactive oxygen species in angiogenesis and preventing tissue injury after brain ischemia. <i>Microvascular Research</i> , 2019, 123, 62-67.	1.1	36
482	New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 187.	1.8	166
483	Mitochondrial Dysfunction in Stroke: Implications of Stem Cell Therapy. <i>Translational Stroke Research</i> , 2019, 10, 121-136.	2.3	37
484	Rapamycin in ischemic stroke: Old drug, new tricks?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 20-35.	2.4	38
485	Noncoding RNAs in the Vascular System Response to Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 992-1010.	2.5	26
486	Reactive Oxygen Species Play a Biphasic Role in Brain Ischemia. <i>Journal of Investigative Surgery</i> , 2019, 32, 97-102.	0.6	25
487	Uric Acid Treatment After Stroke Prevents Long-Term Middle Cerebral Artery Remodelling and Attenuates Brain Damage in Spontaneously Hypertensive Rats. <i>Translational Stroke Research</i> , 2020, 11, 1332-1347.	2.3	16
488	Non-invasive treatment with near-infrared light: A novel mechanisms-based strategy that evokes sustained reduction in brain injury after stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 833-844.	2.4	21
489	Proteomic analysis of protein changes in plasma by balloon test occlusion. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 397-401.	0.8	2
490	Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 96-100.	0.5	5
491	The Protective and Reparative Role of Colony-Stimulating Factors in the Brain with Cerebral Ischemia/Reperfusion Injury. <i>Neuroendocrinology</i> , 2021, 111, 1029-1065.	1.2	9
492	Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7609.	1.8	448
493	Cerebrolysin for acute ischaemic stroke. <i>The Cochrane Library</i> , 2020, 2020, CD007026.	1.5	14
494	Oklahoma Nitron-007: novel treatment for diffuse intrinsic pontine glioma. <i>Journal of Translational Medicine</i> , 2020, 18, 424.	1.8	7
495	Nanomedicine for Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7600.	1.8	52
496	Comorbidity and age in the modelling of stroke: are we still failing to consider the characteristics of stroke patients?Comorbidity and age in the modelling of stroke: are we still failing to consider the characteristics of stroke patients?. <i>BMJ Open Science</i> , 2020, 44, e100013.	0.8	11
497	Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papersAre researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers. <i>BMJ Open Science</i> , 2020, 44, e100041.	0.8	12
498	On the Clinical Pharmacology of Reactive Oxygen Species. <i>Pharmacological Reviews</i> , 2020, 72, 801-828.	7.1	70

#	ARTICLE	IF	CITATIONS
499	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. <i>Antioxidants</i> , 2020, 9, 740.	2.2	52
500	Demystifying Oxidative Stress. <i>Handbook of Experimental Pharmacology</i> , 2020, 264, 3-26.	0.9	10
501	Understanding Evidence. , 2020, , 10-34.		1
502	Pathophysiology of Bloodâ€”Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. <i>Frontiers in Neurology</i> , 2020, 11, 594672.	1.1	192
503	Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117217.	0.3	21
504	Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows. <i>Cells</i> , 2020, 9, 1074.	1.8	32
505	Biomechanics and hemodynamics of stent-retrievers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2350-2365.	2.4	12
506	Selective cerebral cooling for acute ischemic stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1365-1367.	2.4	6
507	Potential circadian effects on translational failure for neuroprotection. <i>Nature</i> , 2020, 582, 395-398.	13.7	85
508	Regulation of Vascular Function and Inflammation via Cross Talk of Reactive Oxygen and Nitrogen Species from Mitochondria or NADPH Oxidaseâ€”Implications for Diabetes Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3405.	1.8	27
509	Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. <i>Free Radical Biology and Medicine</i> , 2020, 157, 15-37.	1.3	97
510	Natalizumab in acute ischemic stroke (ACTION II). <i>Neurology</i> , 2020, 95, e1091-e1104.	1.5	55
511	Mitochondrial Transfer as a Therapeutic Strategy Against Ischemic Stroke. <i>Translational Stroke Research</i> , 2020, 11, 1214-1228.	2.3	36
512	Novel approaches for the delivery of therapeutics in ischemic stroke. <i>Drug Discovery Today</i> , 2020, 25, 535-551.	3.2	32
513	Human in vitro systems for examining synaptic function and plasticity in the brain. <i>Journal of Neurophysiology</i> , 2020, 123, 945-965.	0.9	10
514	Resilience to Injury: A New Approach to Neuroprotection?. <i>Neurotherapeutics</i> , 2020, 17, 457-474.	2.1	6
515	Substituted $\hat{\pm}$ -Phenyl and $\hat{\pm}$ -Naphthyl- <i>N</i> - <i>tert</i> -butyl Nitrones: Synthesis, Spin-Trapping, and Neuroprotection Evaluation. <i>Journal of Organic Chemistry</i> , 2020, 85, 6073-6085.	1.7	16
516	Look closer: The multidimensional patterns of post-stroke burden behind the modified Rankin Scale. <i>International Journal of Stroke</i> , 2021, 16, 420-428.	2.9	13

#	ARTICLE	IF	CITATIONS
517	Phase I safety, tolerability, and pharmacokinetic studies of tetramethylpyrazine nitron in healthy Chinese volunteers. <i>Drug Development Research</i> , 2021, 82, 97-107.	1.4	5
518	Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100007.	0.4	1
519	Neuroprotection by cattle encephalon glycoside and igitonin beyond the time window of thrombolysis in ischemic stroke. <i>Neural Regeneration Research</i> , 2021, 16, 312.	1.6	6
520	The Role of Nanomaterials in Stroke Treatment: Targeting Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	22
521	Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 2021, 52, 772-780.	1.0	78
522	Preclinical Stroke Research and Translational Failure: A Bird's Eye View on Preventable Variables. <i>Cellular and Molecular Neurobiology</i> , 2021, , 1.	1.7	12
523	Small-Molecule Inhibitors of Reactive Oxygen Species Production. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5252-5275.	2.9	26
524	Single-Step Approach toward Nitrones via Pyridinium Ylides: The DMAP-Catalyzed Reaction of Benzyl Halides with Nitrosoarenes. <i>Journal of Organic Chemistry</i> , 2021, 86, 6343-6350.	1.7	6
525	Preclinical animal studies in ischemic stroke: Challenges and some solutions. <i>Animal Models and Experimental Medicine</i> , 2021, 4, 104-115.	1.3	34
526	Translational Block in Stroke: A Constructive and "Out-of-the-Box" Reappraisal. <i>Frontiers in Neuroscience</i> , 2021, 15, 652403.	1.4	21
527	Oxygen-Generating Cyanobacteria Powered by Upconversion-Nanoparticles-Converted Near-Infrared Light for Ischemic Stroke Treatment. <i>Nano Letters</i> , 2021, 21, 4654-4665.	4.5	52
528	Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. <i>Frontiers in Neurology</i> , 2021, 12, 661955.	1.1	78
529	Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase-II Trial: AdrenoMedullin for Ischemic Stroke Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105761.	0.7	4
530	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. <i>Pharmacological Reviews</i> , 2021, 73, 924-967.	7.1	359
531	Brain acute ischemia mechanisms: implications to experimental and clinical treatment. <i>Regional Blood Circulation and Microcirculation</i> , 2021, 20, 5-19.	0.1	2
532	The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 698172.	1.8	50
533	Factors Contributing to an Efficacious Endovascular Treatment for Acute Ischemic Stroke in Asian Population. <i>Neurointervention</i> , 2021, 16, 91-110.	0.5	11
534	Neuroprotective therapy in acute ischemic stroke. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 94-102.	0.2	4

#	ARTICLE	IF	CITATIONS
535	Clinical Scales to Assess Patients With Stroke. , 2022, , 262-280.e6.		0
536	Intravenous Thrombolysis. , 2022, , 750-772.e3.		0
537	Pharmacologic Modification of Acute Cerebral Ischemia. , 2022, , 831-851.e6.		0
538	Molecular aspects of regeneration and neuroprotection in neurotraumatic diseases. , 2021, , 181-224.		0
539	CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, Radicut, and STAZN). , 2012, , 639-656.		1
540	A Critical Review of Stroke Trial Analytical Methodology: Outcome Measures, Study Design, and Correction for Imbalances. , 2012, , 833-861.		10
541	Focal Cerebral Ischemia by Permanent Middle Cerebral Artery Occlusion in Sheep: Surgical Technique, Clinical Imaging, and Histopathological Results. Neuromethods, 2016, , 195-225.	0.2	6
542	NADPH Oxidases and Blood-Brain Barrier Dysfunction in Stroke. , 2010, , 211-230.		2
543	Recent Advances in the Management of Acute Ischemic Stroke. Competency-based Critical Care, 2010, , 61-68.	0.0	2
544	Reflections on Neuroprotection Research and the Path Toward Clinical Success. Springer Series in Translational Stroke Research, 2017, , 3-71.	0.1	2
545	Targeting Pericytes and the Microcirculation for Ischemic Stroke Therapy. Springer Series in Translational Stroke Research, 2017, , 537-556.	0.1	3
546	History of Neuroprotection: Trials and Tribulations. Springer Series in Translational Stroke Research, 2017, , 133-154.	0.1	1
547	Chinese Herbal Medicines for Neuroprotection in Ischemic Stroke: Promise and Reality. , 2013, , 363-395.		2
548	<i>para</i> -Substituted $\hat{\pm}$ -Phenyl- <i>N</i> - <i>tert</i> -butyl Nitrones: Spin-Trapping, Redox and Neuroprotective Properties. ACS Omega, 2020, 5, 30989-30999.	1.6	5
550	Allopregnanolone and Its Precursor Progesterone Do Not Reduce Injury after Experimental Stroke in Hypertensive Rats – Role of Postoperative Temperature Regulation?. PLoS ONE, 2014, 9, e107752.	1.1	6
551	THE ACUTE PERIOD OF ISCHEMIC STROKE: DIAGNOSIS AND TREATMENT. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2009, .	0.2	1
553	Neglecting the null: the pitfalls of underreporting negative results in preclinical research. University of Ottawa Journal of Medicine, 2014, 4, .	0.0	2
554	Apigenin-7- <i>O</i> - $\hat{1}^2$ - <i>D</i> -(-6- <i>p</i> -coumaroyl)-glucopyranoside treatment elicits a neuroprotective effect through GSK-3 $\hat{1}^2$ phosphorylation-mediated Nrf2 activation. Aging, 2020, 12, 23872-23888.	1.4	11

#	ARTICLE	IF	CITATIONS
555	Therapeutic approaches to vascular protection in ischemic stroke. <i>Acta Medica Okayama</i> , 2011, 65, 219-23.	0.1	19
556	The modern concept of neuroprotective therapy in the acute period of ischemic stroke. <i>Meditinskiy Sovet</i> , 2020, , 82-91.	0.1	2
557	Mechanisms of Neurovascular Dysfunction in Acute Ischemic Brain. <i>Current Medicinal Chemistry</i> , 2014, 21, 2035-2042.	1.2	72
558	Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review. <i>Current Neuropharmacology</i> , 2020, 18, 596-612.	1.4	31
559	Neuroprotective strategies for acute ischemic stroke: recent progress and future perspectives. <i>Precision and Future Medicine</i> , 2017, 1, 115-121.	0.5	7
560	Hypoxia inducible factor-1alpha mediates protection of DL-3-n-butylphthalide in brain microvascular endothelial cells against oxygen glucose deprivation-induced injury. <i>Neural Regeneration Research</i> , 2012, 7, 948-54.	1.6	13
561	How should we bridge the missing steps in translational research for stroke therapy?-A critical review. <i>Nosotchu</i> , 2008, 30, 875-880.	0.0	4
562	Stroke management. <i>Annals of Indian Academy of Neurology</i> , 2011, 14, 82.	0.2	32
563	A more consistent intraluminal rhesus monkey model of ischemic stroke. <i>Neural Regeneration Research</i> , 2014, 9, 2087.	1.6	26
564	Brain protein oxidation: what does it reflect?. <i>Neural Regeneration Research</i> , 2015, 10, 1729.	1.6	2
565	Endothelial progenitor cells, potential biomarkers for diagnosis and prognosis of ischemic stroke: protocol for an observational case-control study. <i>Neural Regeneration Research</i> , 2020, 15, 1300.	1.6	15
566	Multiphase adjuvant neuroprotection: A novel paradigm for improving acute ischemic stroke outcomes. <i>Brain Circulation</i> , 2020, 6, 11.	0.7	43
567	Autologous Bone Marrow Stromal Cell Transplantation for Central Nervous System Disorders “Recent Progress and Perspective for Clinical Application. <i>Journal of Stem Cells and Regenerative Medicine</i> , 2011, 7, 2-13.	2.2	20
568	The Future of Stroke Interventions. <i>Rambam Maimonides Medical Journal</i> , 2020, 11, e0018.	0.4	3
569	Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials. <i>Journal of Stroke</i> , 2015, 17, 268-281.	1.4	51
570	Challenges and Pitfalls of Stroke Therapeutics Research. <i>Korean Journal of Stroke</i> , 2011, 13, 11.	0.1	2
571	The Continued Promise of Neuroprotection for Acute Stroke Treatment. <i>Journal of Experimental Stroke & Translational Medicine</i> , 2008, 1, 1-8.	0.2	8
572	We heart cultured hearts. A comparative review of methodologies for targeted differentiation and maintenance of cardiomyocytes derived from pluripotent and multipotent stem cells. <i>BioDiscovery</i> , 0, 14, e8962.	0.1	4

#	ARTICLE	IF	CITATIONS
573	Adjunctive cytoprotective therapies in acute ischemic stroke: a systematic review. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 46.	2.4	8
574	rt-PA TM æ ³ ç TM ,æ ³ ï¼¼šæµ·å-æ-çCE®ãf-ãf“ãf¥ãf¼. <i>Nosotchu</i> , 2008, 30, 755-759.	0.0	0
575	The Continued Promise of Neuroprotection for Acute Stroke Treatment. <i>Journal of Experimental Stroke & Translational Medicine</i> , 2008, 01, .	0.2	0
576	Randomized Clinical Stroke Trials in 2007. <i>The Open Neurology Journal</i> , 2008, 2, 55-65.	0.4	3
577	Antithrombotic and Neuroprotective Therapy in Acute Ischemic Stroke. <i>Journal of the Korean Medical Association</i> , 2009, 52, 356.	0.1	0
578	Neurobiology of Postischemic Recuperation in the Aged Mammalian Brain. , 2009, , 403-451.		0
579	BRAIN METABOLISM, THE PATHOPHYSIOLOGY OF BRAIN INJURY, AND POTENTIAL BENEFICIAL AGENTS AND TECHNIQUES. , 2010, , 1-16.		2
580	The bistable network model of brain ischemia. <i>Journal of Experimental Stroke & Translational Medicine</i> , 2010, 3, 56-58.	0.2	0
581	Bone Marrow Stromal Cell Transplantation for Central Nervous System Disorders: Perspectives for Translational Research and Clinical Application. , 2010, , 126-138.		0
582	The bistable network model of brain ischemia. <i>Journal of Experimental Stroke & Translational Medicine</i> , 2010, 03, .	0.2	0
583	Potential Neuroprotective Strategies for Ischemic Injury. , 2010, , 67-106.		0
584	Oxidative Stress and Mitochondrial Dysfunction in Neurovascular Injury after Stroke(çSPECIAL) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Neurosurgery</i> , 2011, 20, 559-565.	0.0	0
586	Measuring and Analysis of Outcome in Stroke Trials. <i>Korean Journal of Stroke</i> , 2011, 13, 1.	0.1	1
587	Magnesium in Ischemic Stroke and Subarachnoid Hemorrhage. , 2012, , 481-521.		0
588	Implication of Oxidative Stress and æœLabile Ironæ•in the Molecular Mechanisms of Ischemic Stroke. , 2012, , 255-271.		1
589	Brain Angiogenesis After Stroke. , 2013, , 239-260.		1
590	Clinical Outcomes, Stroke Trials, and Cognitive Outcome. , 2014, , 283-314.		1
591	Edaravone Therapy: From Bench to Bedside. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2014, , 211-218.	0.4	0

#	ARTICLE	IF	CITATIONS
592	Neurotoxicity and Stroke. , 2014, , 1483-1509.		0
593	Antioxidants and Neuroprotection. , 2014, , 2175-2189.		2
594	Blood Vessel Remodeling After Stroke. , 2015, , 175-218.		0
595	Recent Efforts to Optimize the Predictive Value of Preclinical Study. Japanese Journal of Neurosurgery, 2015, 24, 592-596.	0.0	0
597	Roles of Neutrophils in Stroke. Springer Series in Translational Stroke Research, 2016, , 273-301.	0.1	0
599	History of Experimental Stroke Research. Springer Series in Translational Stroke Research, 2017, , 123-131.	0.1	0
600	Preparing for Future Stem Cell Clinical Trials. Springer Series in Translational Stroke Research, 2018, , 293-307.	0.1	0
601	Translational research that enables inhibition of hemorrhagic transformation after tPA treatment for ischemic stroke. No Junkan Taisha = Cerebral Blood Flow and Metabolism, 2018, 30, 11-15.	0.1	0
602	Nonlinear Anomalies. , 2018, , 77-95.		0
608	Recruitment of Ischemic Stroke Patients in Clinical trials in General Practice and Implications for Generalizability of Results. Journal of Vascular and Interventional Neurology, 2012, 5, 27-32.	1.1	5
613	The NIHSS Score and its Components can Predict Cortical Stroke. , 2013, 2, 1026.		6
615	Neuroprotective Agents in the Intensive Care Unit: -Neuroprotective Agents in ICU. Journal of Pharmacopuncture, 2018, 21, 226-240.	0.4	1
616	Collateral Circulation Augmentation and Neuroprotection as Adjuvant to Mechanical Thrombectomy in Acute Ischemic Stroke. Neurology, 2021, 97, S178-S184.	1.5	17
617	Oxidative stress-responsive apoptosis inducing protein (ORAIP) plays a critical role in doxorubicin-induced apoptosis in rat cardiac myocytes. International Journal of Cardiology, 2022, 348, 119-124.	0.8	3
618	Neuroprotective Agents in the Intensive Care Unit. Journal of Pharmacopuncture, 2018, 21, 226-240.	0.4	8
619	Potential Role of Exosomes in Ischemic Stroke Treatment. Biomolecules, 2022, 12, 115.	1.8	16
620	Oxycodone relieves permeability damage and apoptosis of oxygen-glucose deprivation/reoxygenation-induced brain microvascular endothelial cells through ras homolog family member A (RhoA)/ Rho-associated coiled-coil containing kinases (ROCK)/ myosin light chain 2 (MLC2) signal. Bioengineered, 2022, 13, 5205-5215.	1.4	4
621	Oxidative Stress in Ischemia/Reperfusion Injuries following Acute Ischemic Stroke. Biomedicines, 2022, 10, 574.	1.4	48

#	ARTICLE	IF	CITATIONS
622	A Primeval Mechanism of Tolerance to Desiccation Based on Glycolic Acid Saves Neurons in Mammals from Ischemia by Reducing Intracellular Calcium-Mediated Excitotoxicity. <i>Advanced Science</i> , 2022, 9, e2103265.	5.6	7
623	Quest for Quality in Translational Stroke Research—A New Dawn for Neuroprotection?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5381.	1.8	6
624	Zebrafish for modeling stroke and their applicability for drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 559-568.	2.5	3
625	Metabolomics-based study of the potential interventional effects of Xiao-Xu-Ming Decoction on cerebral ischemia/reperfusion rats. <i>Journal of Ethnopharmacology</i> , 2022, 295, 115379.	2.0	6
626	Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	19
627	Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities. <i>Progress in Medicinal Chemistry</i> , 2022, , 1-91.	4.1	7
628	Preclinical Characterization of Antioxidant Quinoyl Nitron QN23 as a New Candidate for the Treatment of Ischemic Stroke. <i>Antioxidants</i> , 2022, 11, 1186.	2.2	6
629	Xingnao Kaiqiao Acupuncture Method Combined with Temporal Three-Needle in the Treatment of Acute Ischemic Stroke: A Randomized Controlled Trial. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-7.	1.1	1
630	Brain Energy Metabolism in Ischemic Stroke: Effects of Smoking and Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8512.	1.8	11
631	Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
632	The Therapeutic Potential of Mitochondria Transplantation Therapy in Neurodegenerative and Neurovascular Disorders. <i>Current Neuropharmacology</i> , 2023, 21, 1100-1116.	1.4	5
633	Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial. <i>Stroke</i> , 2022, 53, 3250-3259.	1.0	8
634	Cost-effectiveness of edaravone dextroborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
635	The Role of Oxidative Stress in Acute Ischemic Stroke-Related Thrombosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	1.9	15
637	Stroke and Neurogenesis: Bridging Clinical Observations to New Mechanistic Insights from Animal Models. <i>Translational Stroke Research</i> , 2024, 15, 53-68.	2.3	8
638	Pharmacological Strategies for Stroke Intervention: Assessment of Pathophysiological Relevance and Clinical Trials. <i>Clinical Neuropharmacology</i> , 2023, 46, 17-30.	0.2	0
639	Neuroprotection. , 2022, , 478-490.		0
640	Key design elements of successful acute ischemic stroke treatment trials. <i>Neurological Research and Practice</i> , 2023, 5, .	1.0	2

#	ARTICLE	IF	CITATIONS
641	Glutamate as a Neurotoxin. , 2022, , 769-801.		0
642	Neuroprotective agents in acute ischemic stroke. , 0, , 47-70.		1
643	Evolving Stroke Systems of Care: Stroke Diagnosis and Treatment in the Post-Thrombectomy Era. Neurotherapeutics, 2023, 20, 655-663.	2.1	2